Clinical Trials

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04439201 2026-04-13

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

LymphoidOther hematologic neoplasm

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-04-13

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04557098 2026-04-13

MajesTEC-1

194 enrolled 2 FDA

Hematologic Neoplasms

NCT04634552 2026-04-13

MonumenTAL-1

Other hematologic neoplasmPlasma cell

510 enrolled 2 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04728893 2026-04-13

MK-1026-003

LymphoidOther hematologic neoplasm

490 enrolled

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT07006506 2026-04-13

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

46 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Phase 2 Completed

100 enrolled 38 charts

Hematologic Neoplasms

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CNSClassical hematologyLymphoidOther hematologic neoplasm

70 enrolled

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06926595 2026-04-03

GVHD-PTCy

41 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled 10 charts

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT04438382 2026-04-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Phase 2 Terminated

1 enrolled 1 chart

Hematologic Neoplasms

NCT05873205 2026-04-02

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

12 enrolled

Hematologic Neoplasms

NCT05952804 2026-04-02

IVIG for Infection Prevention After CAR-T-Cell Therapy

150 enrolled

Hematologic Neoplasms

NCT01315132 2026-03-19

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Phase 2 Completed

47 enrolled 8 charts